Avenue Financial Statements From 2010 to 2025

ATXI Stock  USD 1.27  0.02  1.60%   
Avenue Therapeutics financial statements provide useful quarterly and yearly information to potential Avenue Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Avenue Therapeutics financial statements helps investors assess Avenue Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Avenue Therapeutics' valuation are summarized below:
Quarterly Earnings Growth
(0.76)
Market Capitalization
2.6 M
Earnings Share
24.78
We have found one hundred eighteen available fundamental signals for Avenue Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Avenue Therapeutics prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 4.7 B. Enterprise Value is estimated to decrease to about 4.7 B
Check Avenue Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avenue Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 165.9 K, Depreciation And Amortization of 17.6 M or Interest Expense of 350.7 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.02. Avenue financial statements analysis is a perfect complement when working with Avenue Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Avenue Therapeutics Correlation against competitors.
For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.

Avenue Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.6 M1.7 M3.4 M
Pretty Stable
Short and Long Term Debt Total5.4 M6.8 M5.1 M
Slightly volatile
Other Current Liabilities1.1 M914.2 K716.5 K
Slightly volatile
Total Current LiabilitiesM1.1 M2.5 M
Slightly volatile
Current Deferred Revenue1.3 MM1.3 M
Slightly volatile
Accounts Payable342.9 K360.9 K745.1 K
Very volatile
Cash1.9 M2.1 M2.7 M
Slightly volatile
Cash And Short Term Investments1.5 M1.6 M3.2 M
Pretty Stable
Common Stock Total Equity1.5 K2.3 K1.4 K
Slightly volatile
Common Stock Shares Outstanding154.3 K162.4 K686 K
Very volatile
Long Term Debt Total1.9 M1.8 M2.3 M
Slightly volatile
Liabilities And Stockholders Equity1.6 M1.7 M3.4 M
Pretty Stable
Capital Surpluse91.3 M87 M39.8 M
Slightly volatile
Other Stockholder Equity59.9 M106.4 M41 M
Slightly volatile
Total LiabilitiesM1.1 M3.6 M
Slightly volatile
Short and Long Term Debt3.1 M3.5 M3.8 M
Slightly volatile
Total Current Assets1.6 M1.7 M3.4 M
Pretty Stable
Short Term Debt2.8 M4.4 M2.8 M
Slightly volatile
Common Stock1.8 K3.5 K1.6 K
Slightly volatile
Other Assets57.3 K60.3 K339.1 K
Slightly volatile
Other Current Assets57.3 K60.3 K248 K
Slightly volatile
Net Receivables72 K81 K88.3 K
Slightly volatile

Avenue Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income165.9 K113.4 K253.8 K
Slightly volatile
Selling General Administrative3.3 M4.8 M2.5 M
Slightly volatile
Other Operating Expenses12 M16.7 M9.5 M
Slightly volatile
Research Development8.7 M11.9 MM
Slightly volatile
Total Operating Expenses12 M16.7 M9.5 M
Slightly volatile
Non Recurring882.4 K992.7 K1.1 M
Slightly volatile
Selling And Marketing Expenses3.3 M3.8 M4.1 M
Slightly volatile

Avenue Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow1.9 M2.1 M2.7 M
Slightly volatile
Stock Based Compensation923.3 KM553 K
Slightly volatile
Begin Period Cash Flow5.1 M7.7 M3.1 M
Slightly volatile
Depreciation163.3 K200.1 K152.7 K
Slightly volatile
Cash Flows Other Operating48.7 K51.3 K895.9 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Cash Per Share10.2314.546.7899
Slightly volatile
Income Quality0.710.820.6503
Slightly volatile
Current Ratio2.491.391.9929
Slightly volatile
Graham Number16515765.6528
Slightly volatile
Capex Per Share20.1119.158.7501
Slightly volatile
Interest Debt Per Share0.580.613.9043
Slightly volatile
Debt To Assets32.5834.29123
Slightly volatile
Ebt Per Ebit1.060.830.994
Slightly volatile
Quick Ratio2.491.391.9929
Slightly volatile
Cash Ratio2.061.341.6646
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio2.531.522.5124
Slightly volatile
Debt Ratio32.5834.29123
Slightly volatile

Avenue Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.7 B6.6 B5.9 B
Slightly volatile
Enterprise Value4.7 B6.6 B5.9 B
Slightly volatile

Avenue Fundamental Market Drivers

Forward Price Earnings17.9856
Cash And Short Term Investments1.8 M

Avenue Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Avenue Therapeutics Financial Statements

Investors use fundamental indicators, such as Avenue Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Avenue Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred RevenueM1.3 M

Currently Active Assets on Macroaxis

When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:
Check out the analysis of Avenue Therapeutics Correlation against competitors.
For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Earnings Share
24.78
Return On Assets
(4.72)
Return On Equity
(5.35)
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.